Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1971 1
1972 1
1973 4
1974 2
1975 7
1976 7
1977 5
1978 11
1979 4
1980 10
1981 16
1982 9
1983 14
1984 11
1985 12
1986 24
1987 13
1988 16
1989 13
1990 6
1991 6
1992 9
1993 6
1994 7
1995 4
1996 7
1997 2
1998 5
1999 3
2000 1
2001 4
2002 1
2003 2
2004 1
2005 1
2006 1
2007 2
2008 2
2009 2
2010 1
2011 4
2012 3
2013 1
2015 1
2019 1
2020 1
2021 1
2024 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

268 results

Results by year

Filters applied: . Clear all
Page 1
Planned release dihydroergotamine in common migraine and "tension-vascular headache": multicentre clinical trial.
Fontanari D, Perulli L, Conte F, Tambato E, Toso V, Zanetti R. Fontanari D, et al. Cephalalgia. 1983 Aug;3 Suppl 1:189-91. doi: 10.1177/03331024830030S133. Cephalalgia. 1983. PMID: 6352048 Clinical Trial.
The antimigraine efficacy of dihydroergotamine methanesulphonate in the pharmaceutical form of planned release capsules has been evaluated. ...
The antimigraine efficacy of dihydroergotamine methanesulphonate in the pharmaceutical form of planned release capsules has been eval …
Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis.
Clagett GP, Reisch JS. Clagett GP, et al. Ann Surg. 1988 Aug;208(2):227-40. doi: 10.1097/00000658-198808000-00016. Ann Surg. 1988. PMID: 2456748 Free PMC article. Review.
Low-dose heparin (LDH), dextran, heparin-dihydroergotamine (HDHE), intermittent pneumatic compression (IPC), and graded elastic stockings significantly reduced the incidence of DVT; aspirin was ineffective. ...
Low-dose heparin (LDH), dextran, heparin-dihydroergotamine (HDHE), intermittent pneumatic compression (IPC), and graded elastic stock …
Dihydroergokryptine versus dihydroergotamine in migraine prophylaxis: a double-blind clinical trial.
Frediani F, Grazzi L, Zanotti A, Mailland F, Zappacosta BM, Bussone G. Frediani F, et al. Cephalalgia. 1991 Jul;11(3):117-21. doi: 10.1046/j.1468-2982.1991.1103117.x. Cephalalgia. 1991. PMID: 1909603 Clinical Trial.
Dihydroergokryptine has been evaluated in the prophylaxis of headache attacks in patients with migraine without aura. The study was controlled vs dihydroergotamine with a double-blind crossover design. After a 1-month run-in period, 30 patients were randomized into two gro …
Dihydroergokryptine has been evaluated in the prophylaxis of headache attacks in patients with migraine without aura. The study was controll …
Human pharmacokinetics of dihydroergotamine administered by nasal spray.
Humbert H, Cabiac MD, Dubray C, Lavène D. Humbert H, et al. Clin Pharmacol Ther. 1996 Sep;60(3):265-75. doi: 10.1016/S0009-9236(96)90053-3. Clin Pharmacol Ther. 1996. PMID: 8841149 Clinical Trial.
OBJECTIVES: A nasal spray of dihydroergotamine was developed for the treatment of migraine headaches, and pharmacokinetic studies were scheduled to evaluate the bioavailability of dihydroergotamine by this new route of administration. ...The presence of acute viral …
OBJECTIVES: A nasal spray of dihydroergotamine was developed for the treatment of migraine headaches, and pharmacokinetic studies wer …
Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine.
Dafer RM, Tietjen GE, Rothrock JF, Vann RE, Shrewsbury SB, Aurora SK. Dafer RM, et al. Headache. 2024 Sep;64(8):983-994. doi: 10.1111/head.14669. Epub 2024 May 27. Headache. 2024. PMID: 38800847 Clinical Trial.
OBJECTIVE: To report the cardiovascular (CV) safety of dihydroergotamine mesylate (DHE) administered by precision olfactory delivery (INP104) from two clinical trials. ...
OBJECTIVE: To report the cardiovascular (CV) safety of dihydroergotamine mesylate (DHE) administered by precision olfactory delivery …
Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study.
Tepper SJ, Albrecht D, Ailani J, Kirby L, Strom S, Rapoport AM. Tepper SJ, et al. CNS Drugs. 2024 Dec;38(12):1017-1027. doi: 10.1007/s40263-024-01118-8. Epub 2024 Oct 7. CNS Drugs. 2024. PMID: 39373843 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVE: STS101 is an investigational drug-device combination comprising 5.2 mg dihydroergotamine (DHE) powder (6.0 mg DHE mesylate) in a single-use nasal delivery device for the acute treatment of migraine. ...
BACKGROUND AND OBJECTIVE: STS101 is an investigational drug-device combination comprising 5.2 mg dihydroergotamine (DHE) powder (6.0 …
Bioavailability of intranasal formulations of dihydroergotamine.
van der Kuy PH, Lohman JJ, Hooymans PM, Ter Berg JW, Merkus FW. van der Kuy PH, et al. Eur J Clin Pharmacol. 1999 Nov;55(9):677-80. doi: 10.1007/s002280050692. Eur J Clin Pharmacol. 1999. PMID: 10638398 Clinical Trial.
OBJECTIVE: A comparison of the pharmacokinetic properties of two novel intranasal preparations of dihydroergotamine mesilate (DHEM) with a commercially available intranasal preparation. METHODS: Two intranasal formulations of DHEM in combination with randomly methylated be …
OBJECTIVE: A comparison of the pharmacokinetic properties of two novel intranasal preparations of dihydroergotamine mesilate (DHEM) w …
Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis. A multicenter trial. The Multicenter Trial Committee.
[No authors listed] [No authors listed] JAMA. 1984 Jun 8;251(22):2960-6. doi: 10.1001/jama.1984.03340460038022. JAMA. 1984. PMID: 6371278 Clinical Trial.
Daily radiofibrinogen uptake tests revealed the following DVT rates: Dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 5,000 IU, 9.4%; dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 2,500 IU, 16.8%; heparin sodium, 5,000 IU alone, 16.8%; dihydroe …
Daily radiofibrinogen uptake tests revealed the following DVT rates: Dihydroergotamine mesylate, 0.5 mg, plus heparin sodium, 5,000 I …
Outpatient home-based continuous intravenous dihydroergotamine therapy for intractable migraine.
Charles JA, von Dohln P. Charles JA, et al. Headache. 2010 May;50(5):852-60. doi: 10.1111/j.1526-4610.2010.01622.x. Epub 2010 Jan 28. Headache. 2010. PMID: 20132337 Clinical Trial.
We conducted a study to determine efficacy, tolerability, and feasibility to treat patients with daily intractable headache with continuous intravenous dihydroergotamine in an outpatient home-based setting. METHODS: A total of 31 patients fulfilling ICHD-II criteria for ch …
We conducted a study to determine efficacy, tolerability, and feasibility to treat patients with daily intractable headache with continuous …
Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.
Bodie S, Curran AK, Gonzalez-Nelson AC, Perry JM, Manning DC, Wasilewski MM. Bodie S, et al. Headache. 2024 Jun;64(6):643-651. doi: 10.1111/head.14731. Epub 2024 May 8. Headache. 2024. PMID: 38717120 Clinical Trial.
BACKGROUND: Intravenous dihydroergotamine (DHE) has well-established efficacy for the acute treatment of migraine, but its use is limited by the need for in-hospital administration and the nausea/vomiting associated with a high maximum plasma concentration (C(max)). ...
BACKGROUND: Intravenous dihydroergotamine (DHE) has well-established efficacy for the acute treatment of migraine, but its use is lim …
268 results